Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas

Clinical Cancer Research

Volumn 5, Issue 5, 1999, Pages 985-990

  Debinski, Waldemar ^a   Gibo, Denise M ^a   Hulet, Stanley W ^a   Connor, James R ^a   Gillespie, G Yancey ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4;

ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TARGETING; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOREGULATION; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ADOLESCENT; ADULT; AGED; ANIMALS; BRAIN CHEMISTRY; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOTOXINS; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; INTERLEUKIN-4; MALE; MICE; MICE, NUDE; MICE, SCID; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NERVE TISSUE PROTEINS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-13; RECOMBINANT PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032901749     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Davis, F. G., Freels, S., Grutsch, J., Barlas, S., and Brem, S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J. Neurosurg., 88: 1-10, 1998.
2. Reports from the front. Science (Washington DC), 267: 1414, 1995.
3. Debinski, W., Obiri, N. I., Powers, S. K., Pastan, I., and Puri, R. K. Human glioma cells over-express receptor for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin. Cancer Res., 1: 1253-1258, 1995.
4. Debinski, W., Miner, R., Leland, P., Obiri, N. I., and Puri, R. K. Receptor for IL13 does not interact with LL4 but receptor for IL4 interacts with IL13 on human glioma cells. J. Biol. Chem., 271: 22428-22433, 1996.
5. McKenzie, A. N. J., Culpepper, J. A., De Waal Malefyt, R., Briere, F., Punnonen, J., Aversa, G., Sato, A., Dang, W., Cocks, B. G., Menon, S., De Vries, J. E., Banchereau, J., and Zurawski, G. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc. Natl. Acad. Sci. USA, 90: 3735-3739, 1993.
6. Minty, A., Chalon, P., Derocq, J. M, Dumont, X, Guillemot, J. C., Kaghad, M., Labit, C., Leplatois, P., Liauzun, P., Miloux, B., Minty, C., Casellas, P., Loison, G., Lupker, J., Shire, D., Ferrara, P., and Caput, D. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature (Lond.), 362: 248-251, 1993.
7. Debinski, W., Obiri, N. I., Pastan, I., and Puri, R. K. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem., 270: 16775-16780, 1995.
8. Murata, T., Obiri, N. I., Debinski, W., and Puri, R. K. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem. Biophys. Res. Commun., 238: 92-94, 1997.
9. Obiri, N. I., Leland, P., Murata, T., Debinski, W., and Puri, R. K. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J. Immunol., 158: 756-764, 1997.
10. Lorimer, I. A. J., Wikstrand, C. J., Batra, S. K., Bigner, D. D., and Pastan, I. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin. Cancer Res., 1: 859-864, 1995.
11. Zellner, A., Fetell, M. R., Bruce, J. N., De Vivo, D. C., and O'Driscoll, K. R. Disparity in expression of protein kinase C a in human glioma versus glioma-derived primary cell lines: therapeutic implications. Clin. Cancer Res., 4: 1797-1802, 1998.
12. Debinski, W., Gibo, D. M., Obiri, N. I., Kealiher, A., and Puri, R. K. Novel anti-brain tumor cytotoxins specific for cancer cells. Nat. Biotechnol., 16: 449-453, 1998.
13. Hulet, S. W., Hess, E., Debinski, W., Arosio, P., Bruce, K., Powers, S. K., and Connor, J. R. Characterization and distribution of ferritin receptors in the mouse brain. I. Neurochem., 72: 868-874, 1999.
14. Debinski, W., Gibo, D. M., and Puri, R. K. Novel way to increase targeting specificity to a human glioblastoma-associated receptor for interleukin 13. Int. J. Cancer, 76: 547-551, 1998.
15. Jefferies, W. A., Brandon, M. R., Hunt, S. V., Williams, A. F., Gatter, K. C., and Mason, D. Y. Transferrin receptor on endothelium of brain capillaries. Nature (Lond.), 312: 162-163, 1984.
16. Zurawski, S. M., Vega, F., Jr., Huyghe, B., and Zurawski, G. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J., 12: 2663-2670, 1993.
17. Youle, R. J. Immunotoxins for central nervous system malignancy. Semin. Cancer Biol., 7: 65-70, 1996.
18. Laske, D. W., Youle, R. J., and Oldfield, E. H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med., 3: 1362-1368, 1997.
19. Wersall, P., Ohlsson, I., Biberfeld, P., Collins, V., von Krusenstjerna, Larsson, S., Mellstedt, H., and Boethius, J. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol. Immunother., 44: 157-164, 1997.
20. Laske, D. W., Ilercil, O., Akbasak, A., Youle, R. J., and Oldfield, E. H. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J. Neurosurg., 80: 520-526, 1994.
21. Gladson, C. L., Wilcox, J. N., Sanders, L., Gillespie, G. Y., and Cheresh, D. A. Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J. Cell Sci., 108: 947-956, 1995.
22. Shrikant, P., and Benveniste, T. The central nervous system as an immunocompetent organ. J. Immunol., 157: 1819-1822, 1996.
23. VanMeir, E. G. Cytokines and the tumors of the central nervous system. Glia, 15: 264-288, 1995.
24. Gillespie, G. Y. Cytokines as modulators of malignant glioma progression. In: R. R. Ransohoff, and E. N. Benveniste (eds.), Cytokines and the CNS: Development, Defense, and Disease, pp. 269-286. Boca Raton, FL: CRC Press, 1996.
25. Jaworski, D. M., Kelly, G. M., Piepmeier, J. M., and Hockfield, S. BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Res., 56: 2293-2298, 1996.
26. Murphy, E. V., Zhang, Y., Zhu, W., and Biggs, J. The human glioma pathogenesis-related proteins structurally related to plant pathogenesis-related proteins and its gene expressed specifically in brain tumors. Gene, 159: 131-135, 1995.
27. Ullrich, N., Gillespie, G. Y., and Sontheimer, H. Human astrocytoma cells express a unique chloride current. NeuroReports, 7: 343-347, 1996.